How long dengue vaccine protection lasts in areas where dengue is common
Long-term durability of DENV-specific immunity after vaccination in a dengue-endemic population
['FUNDING_U01'] · UNIVERSITY OF RHODE ISLAND · NIH-11309098
This project looks at immune responses after dengue vaccination to find which people keep protection longest in places where dengue is common.
Quick facts
| Phase | ['FUNDING_U01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF RHODE ISLAND (nih funded) |
| Locations | 1 site (KINGSTON, UNITED STATES) |
| Trial ID | NIH-11309098 on ClinicalTrials.gov |
What this research studies
Researchers are studying blood samples from people who received the CYD-TDV dengue vaccine to understand why some people keep antibody protection for many years while others do not. They will examine B and T immune cells, measure antibody levels, and use gene-expression and epigenetic tests (like ATAC-seq) on dengue-specific cells collected soon after vaccination. The team will link those early immune signatures to long-term antibody persistence using samples from a phase III trial cohort followed since 2011. Results aim to point to markers that predict lasting protection and inform better vaccine or booster decisions.
Who could benefit from this research
Good fit: Ideal candidates are people from dengue-endemic areas who previously received the CYD-TDV dengue vaccine in a clinical trial and can provide or have provided follow-up blood samples.
Not a fit: People who have never received a dengue vaccine or cannot provide blood samples are unlikely to directly participate or benefit from this project.
Why it matters
Potential benefit: If successful, this work could identify immune markers that predict long-lasting protection and guide who may need booster shots or improved vaccines.
How similar studies have performed: A licensed dengue vaccine (CYD-TDV) and other vaccine trials exist, but applying detailed cell-level transcriptomic and epigenetic profiling to predict long-term immunity is a relatively new approach.
Where this research is happening
KINGSTON, UNITED STATES
- UNIVERSITY OF RHODE ISLAND — KINGSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ROTHMAN, ALAN L — UNIVERSITY OF RHODE ISLAND
- Study coordinator: ROTHMAN, ALAN L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.